

TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

ADVISORY COMMITTEE

December 15, 2006

REFERENCES

Topic I: FDA's risk assessment for potential exposure to vCJD in human plasma-derived antihemophilic factor (FVIII) products and communication material

1. Fischhoff, Baruch. Risk Perception and Communication Unplugged: Twenty years of Progress. *Risk Analysis* 1995; 15 (2): 137-145.
2. Hilton DA et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *Journal of Pathology* 2004; 203: 733-739.
3. Clark P and AC Ghani. Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. *J. R. Soc. Interface* 2005; 2: 19-31.

Topic II: Levels of TSE clearance in the manufacture of plasma-derived FVIII

1. Foster PR. Removal of TSE agents from blood products. *Vox Sanguinis* 2004; 87 (Suppl. 2): 7-10.
2. Lee DC et al. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. *Transfusion Complications* 2001; 41: 449-455.
3. Safar JG, et al. Human prions and plasma lipoproteins. *PNAS* 2006; 103: 11312-11317.